Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies - PubMed (original) (raw)

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

J R Mascola et al. Nat Med. 2000 Feb.

Abstract

The development of the human immunodeficiency virus-1 (HIV-1)/simian immunodeficiency virus (SIV) chimeric virus macaque model (SHIV) permits the in vivo evaluation of anti-HIV-1 envelope glycoprotein immune responses. Using this model, others, and we have shown that passively infused antibody can protect against an intravenous challenge. However, HIV-1 is most often transmitted across mucosal surfaces and the intravenous challenge model may not accurately predict the role of antibody in protection against mucosal exposure. After controlling the macaque estrous cycle with progesterone, anti-HIV-1 neutralizing monoclonal antibodies 2F5 and 2G12, and HIV immune globulin were tested. Whereas all five control monkeys displayed high plasma viremia and rapid CD4 cell decline, 14 antibody-treated macaques were either completely protected against infection or against pathogenic manifestations of SHIV-infection. Infusion of all three antibodies together provided the greatest amount of protection, but a single monoclonal antibody, with modest virus neutralizing activity, was also protective. Compared with our previous intravenous challenge study with the same virus and antibodies, the data indicated that greater protection was achieved after vaginal challenge. This study demonstrates that antibodies can affect transmission and subsequent disease course after vaginal SHIV-challenge; the data begin to define the type of antibody response that could play a role in protection against mucosal transmission of HIV-1.

PubMed Disclaimer

Cited by

Non-Antiretroviral Microbicides for HIV Prevention.
Scott Y, Dezzutti CS. Scott Y, et al. AIDS Rev. 2016 Jul-Sep;18(3):145-150. AIDS Rev. 2016. PMID: 27438574 Free PMC article.
Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection.
Eda Y, Murakami T, Ami Y, Nakasone T, Takizawa M, Someya K, Kaizu M, Izumi Y, Yoshino N, Matsushita S, Higuchi H, Matsui H, Shinohara K, Takeuchi H, Koyanagi Y, Yamamoto N, Honda M. Eda Y, et al. J Virol. 2006 Jun;80(11):5563-70. doi: 10.1128/JVI.02095-05. J Virol. 2006. PMID: 16699037 Free PMC article.
Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody.
Zhang MY, Xiao X, Sidorov IA, Choudhry V, Cham F, Zhang PF, Bouma P, Zwick M, Choudhary A, Montefiori DC, Broder CC, Burton DR, Quinnan GV Jr, Dimitrov DS. Zhang MY, et al. J Virol. 2004 Sep;78(17):9233-42. doi: 10.1128/JVI.78.17.9233-9242.2004. J Virol. 2004. PMID: 15308718 Free PMC article.
Engineering and characterising a novel, highly potent bispecific antibody iMab-CAP256 that targets HIV-1.
Moshoette T, Ali SA, Papathanasopoulos MA, Killick MA. Moshoette T, et al. Retrovirology. 2019 Nov 8;16(1):31. doi: 10.1186/s12977-019-0493-y. Retrovirology. 2019. PMID: 31703699 Free PMC article.

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies - PubMed (original) (raw)